Fundraising Fox
Primmune Therapeutics
Carlsbad, US · Founded 2017 · 9 employees on LinkedIn · 6 known investors
Find your way into Primmune Therapeutics
Sign up to see every warm intro you have to Primmune Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Primmune Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Founders & leadership
Primmune Therapeutics was founded in 2017 by James Appleman, Paulo Rangel, and Stephen Webber.
Board
Investors · 6
How we know: BioRock Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · funding news · Not right? Tell us
How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Funding
SEC filings, press & company announcements$20.1M disclosed across 5 of 7 rounds · 2017–2026
- Undisclosed amountSeries BJan 2026 · 2 sourcesSource ↗
▶$13MraisedNov 2020 · 12 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer
- Scott MorensteinDirector
- Andrew RubinsteinDirector
- Amir NashatDirector
- Offering amount
- $24M
- Amount sold
- $13M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.1MraisedMar 2020 · 19 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $4M
- Amount sold
- $1.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2MraisedMar 2020 · 17 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.5MraisedMar 2020 · 2 investors · PharmaceuticalsRule 506(b)
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $3.5M
- Amount sold
- $2.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.5MraisedJan 2018 · 36 investors · Other TechnologyRule 506(b)
- Todd J HarrisDirector
- Paulo S RangelExecutive Officer, Director
- James R ApplemanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Proceeds to insiders
- $360K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Primmune Therapeutics do?
- Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
- Who founded Primmune Therapeutics?
- Primmune Therapeutics was founded by James Appleman, Paulo Rangel, Stephen Webber in 2017.
- Who are Primmune Therapeutics's investors?
- Primmune Therapeutics's investors include BioBrit, BioRock Ventures, Samsara BioCapital, Bioqube Ventures, Oberland Capital, Polaris Partners.
- How much funding has Primmune Therapeutics raised?
- Primmune Therapeutics has disclosed $20.1M raised across 5 of its 7 known rounds.
- Where is Primmune Therapeutics headquartered?
- Primmune Therapeutics is headquartered in Carlsbad, US.